Skip to content

    Sigachi Industries Limited

    SIGACHI
    Healthcare·30 May 2025
    Management Summary

    Sigachi Industries Limited delivered a strong Q4 and FY25, marked by robust revenue and EBITDA growth driven by its core MCC business. The company is strategically expanding MCC capacity, progressing with its CCS project, and successfully entering regulated API markets. While API revenue saw a temporary dip due to a focus on higher-margin products, the overall outlook remains positive with targets for sustained revenue growth and margin expansion, supported by operational efficiencies and diversification efforts.

    Highlights

    5
    • FY25 total operating income reached INR 500 crores, representing a 25.42% increase over FY24.

    • FY25 EBITDA grew 46.21% to INR 112 crores, with margin improving to 22.38%.

    • Q4 FY25 operating income increased by 23.15% year-on-year to INR 128 crores.

    • Q4 FY25 EBITDA expanded significantly by 74.84% year-on-year to INR 28.5 crores, reflecting a 22.31% margin.

    • Secured CEP certification for Metformin HCL, enabling entry into regulated European markets.

    Concerns

    2
    • API segment revenue declined from INR 57 crores in FY24 to INR 29 crores in FY25, though management attributes this to a strategic shift towards higher-margin products.

    • Promoter pledging increased from 23% to 44%, which management explained was for investing in preferential equity shares for the company's benefit.

    What Changed2

    vs Q2 FY26

    Guidance items14 → 8 (-6)Risks discussed4 → 2 (-2)
    Key financials

    Metrics

    10

    Periods

    2

    Q4

    5
    • Total Operating Income
      ₹128 Cr
      YoY+23.2%
    • EBITDA
      ₹28.5 Cr
      YoY+74.8%
    • EBITDA Margin
      22.3%
    • Net Profit
      ₹16.2 Cr
      YoY+7.3%
    • PAT Margin
      12.6%

    FY25

    5
    • Total Operating Income
      ₹500 Cr
      YoY+25.4%
    • EBITDA
      ₹112 Cr
      YoY+46.2%
    • EBITDA Margin
      22.4%
    • Net Profit
      ₹70.5 Cr
      YoY+23.3%
    • PAT Margin
      14.1%

    Segment breakdown

    • MCC Segment₹409 Cr85.4%
    • O&M Segment₹41 Cr8.6%
    • API Segment₹29 Cr6.1%
    Donut· Share of Revenue (FY25)

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    ₹90 crores

    Debt

    Debt disclosed

    M&A

    Respilon

    joint venture · announced

    M&A

    Trimax

    acquisition · integrated

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    Revenue Growth
    >25%
    High
    Revenue
    O&M Segment Revenue
    INR 75 crores
    High
    Profitability
    EBITDA Margin
    >25%
    Medium
    Profitability
    API Segment EBITDA Margin
    >25%
    Medium
    Capacity
    MCC Capacity
    25,000 MTPA
    Medium
    Operations
    CCS Plant Commercialization
    October 2026
    High
    Efficiency
    CCS Asset Turnover
    3-4x
    High
    Product Pipeline
    CEP Filings
    5
    High

    MCC Capacity Utilization (new plant)

    FY26
    Current68%
    TargetHigher utilization towards full capacity

    Why it matters

    Indicates efficiency and revenue potential from recently commissioned assets.

    Our newly commissioned 7,000 metric ton per annum plant capacity is operating at 68% utilization, expected to scale near full capacity by FY '26.

    How to verify

    key_financials.segment_breakdown[name='MCC']

    Risks & concerns

    2
    RiskSeverity

    API segment revenue decline

    API revenue declined from INR 57 crores in FY24 to INR 29 crores in FY25, attributed by management to a strategic shift to higher-margin products.Analyst acknowledged

    medium

    Promoter pledging increase

    Promoter pledging increased from 23% to 44%, which management stated was for investing in preferential equity shares for the company and can be reduced.Analyst acknowledged

    medium

    Q&A highlights

    8

    “So Satyam, our revenue outlook continues to be driven by the fact that we will deliver more than 25% growth over the next 2 to 3 years. The core drivers would continue to be our excipients and over the next 1 year and the second year, it will add up also as API and O&M. In terms of funding requirements, of course, to add in capacities, there would be funds we would need funding requirements. We really haven't consolidated how much it would be and the way in which we'll be fundraising. They are yet to be kind of finalized and shared.”

    Provides management's long-term growth target and key drivers, while indicating capex funding is still being planned.

    asked by Satyam from Profit Market Securities

    2 min read5 chapters

    Detailed Narrative

    01

    Robust Financial Performance and Core MCC Business Growth

    Sigachi Industries delivered strong financial results for Q4 FY25 and the full fiscal year. FY25 total operating income grew 25.42% to INR 500 crores, with EBITDA expanding 46.21% to INR 112 crores, achieving a margin of 22.38%. The core Microcrystalline Cellulose (MCC) business was a primary driver, with FY25 revenue increasing 35.75% to INR 409 crores and volumes up 29.57%, supported by robust demand in both domestic and international markets. The company aims to sustain revenue growth exceeding 25% over the next 2-3 years and achieve EBITDA margins beyond 25%.

    02

    Strategic Capacity Expansion and Product Mix Optimization

    The company's newly commissioned 7,000 metric ton per annum MCC plant is currently operating at 68% utilization and is targeted to reach full capacity by FY26. This will be achieved through debottlenecking and small capex additions, allowing capacity to increase up to 25,000 MTPA without major new plant investments. Sigachi is also focusing on improving its sales mix by prioritizing special grade products and co-processed excipients, which offer higher margins, contributing to both revenue and margin expansion.

    03

    Diversification into API and O&M Services

    Sigachi is actively diversifying its revenue streams through its API and Operations & Maintenance (O&M) segments. The API arm, Trimax, acquired in August 2023, saw FY25 revenue of INR 29 crores, a strategic shift from FY24's INR 57 crores to focus on higher-margin products and regulated markets. The company has secured CEP certification for Metformin HCL, enabling entry into Europe, and plans to file 5 more CEPs in CY25. The O&M service business is projected to grow significantly, targeting INR 75 crores in FY26 from INR 41 crores in FY25, with new client additions like Adani Solar.

    04

    New Growth Avenues: CCS Plant and Enhanced R&D

    The company is advancing its Cellulose Compaction System (CCS) project, having secured environmental clearance for its facility at Dahej-2 SEZ. Commercialization of this INR 90 crore plant is targeted for October 2026, with INR 40-50 crores expected to be spent in the current fiscal year and INR 55-60 crores funded through debt. This project is anticipated to achieve an asset turnover of 3-4x within 2-3 years post-commissioning. Furthermore, Sigachi has established a state-of-the-art R&D center in Hyderabad to accelerate API development, analytical research, and product innovation.

    05

    Capital Allocation and Shareholder Value Focus

    Management's capital allocation strategy supports its growth trajectory, with planned capex for the CCS project and ongoing debottlenecking for MCC. While promoter pledging increased to 44% to fund preferential equity shares for company investment, management confirmed the proceeds were utilized for the company and that they have the ability to reduce the pledging. The company remains committed to operational excellence, strengthening its core businesses, and delivering long-term value to stakeholders.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.